Triumvira Immunologics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Triumvira Immunologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11089
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Triumvira Immunologics Inc (Triumvira) is a biopharmaceutical company developing engineered T cell therapies for the treatment of multiple cancers. Its proprietary immuno-oncology platform T cell Antigen Coupler (TAC), enables natural T cell receptor to induce a controlled, tumor-specific response with reduced toxicities and thus eliminates solid tumors. The company’s lead product candidate CD19-TAC01, is targeted for the treatment of CD19 positive B-cell malignancies such as Diffuse Large B Cell Lymphoma (DLBCL). Triumvira seeks to work in partnership with other pharmaceutical companies for collaboration and licensing opportunities of its TAC technology platform. The company has operations with research facilities in Hamilton, Canada. Triumvira is headquartered in Austin, Texas, the US.

Triumvira Immunologics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Triumvira Immunologics Raises USD1.4 Million in Seed Financing Round 10
Licensing Agreements 11
Centre for Commercialization of Cancer Immunotherapy Enters into Licensing Agreement with Triumvira Immunologics 11
Triumvira Immunologics Enters into Licensing Agreement with McMaster University 12
Triumvira Immunologics Inc – Key Competitors 13
Triumvira Immunologics Inc – Key Employees 14
Triumvira Immunologics Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Corporate Communications 16
Jun 25, 2018: Triumvira Immunologics Names Scott Smith As Board Director 16
Jun 11, 2018: Triumvira Names Donna Rill As Chief Technology Officer 17
Apr 05, 2018: Triumvira Immunologics Appoints Cynthia Collins to Board of Directors 18
Jan 04, 2018: Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer 19
Product News 20
Aug 03, 2018: Nature Communications publishes studies comparing Triumvira’s T cell antigen coupler (TAC) technology with CAR T cell therapy 20
04/30/2018: Triumvira Immunologics to Present at Two Upcoming Conferences: International Society for Cellular Therapy and Bloom Burton & Co. Healthcare Investor Conference 21
03/22/2018: Triumvira Immunologics to Present at the 25th BioCentury Future Leaders Conference 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Triumvira Immunologics Raises USD1.4 Million in Seed Financing Round 10
Centre for Commercialization of Cancer Immunotherapy Enters into Licensing Agreement with Triumvira Immunologics 11
Triumvira Immunologics Enters into Licensing Agreement with McMaster University 12
Triumvira Immunologics Inc, Key Competitors 13
Triumvira Immunologics Inc, Key Employees 14
Triumvira Immunologics Inc, Other Locations 15

List of Figures
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Triumvira Immunologics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GE Healthcare LLC-医療機器分野:企業M&A・提携分析
    Summary GE Healthcare LLC (GE Healthcare) a business unit of General Electric Company, is a global medical device provider that designs, develops, manufactures, and distributes diagnostic imaging and clinical systems; products and services for drug discovery, biopharmaceutical manufacturing and cell …
  • The Straits Trading Co Ltd:企業の戦略・SWOT・財務情報
    The Straits Trading Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Straits Trading Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Innovent Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that discovers, develops and manufactures monoclonal antibodies. The company offers monoclonal antibodies such as IBI301, IBI302 and IBI303, among others. Its products are used for the treatment of non-Hodgkin’s lymph …
  • iXBlue SAS:企業の戦略的SWOT分析
    iXBlue SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • PolyNovo Ltd (PNV)-医療機器分野:企業M&A・提携分析
    Summary PolyNovo Ltd (PolyNovo), formerly Calzada Ltd is a medical device company that develops, manufactures and commercializes biodegradable polymers for use in medical devices. The company offers products such as biodegradable temporizing matrix and negative pressure wound therapy dressing system …
  • Redx Pharma Plc (REDX):企業の財務・戦略的SWOT分析
    Summary Redx Pharma Plc (Redx Pharma), formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s pipeline products include inhibitors for oncology and anti-infectives for treatment of diseases that include influenza …
  • Lantronix, Inc. (LTRX):企業の財務・戦略的SWOT分析
    Lantronix, Inc. (LTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • AccentCare Inc:企業の戦略的SWOT分析
    AccentCare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Saskatchewan Telecommunications Holding Corporation:企業の戦略的SWOT分析
    Saskatchewan Telecommunications Holding Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compe …
  • Vodacom Group Ltd (VOD):企業の財務・戦略的SWOT分析
    Vodacom Group Ltd (VOD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Obton AS:電力:M&Aディール及び事業提携情報
    Summary Obton A/S (Obton) is an investment company that offers management of assets within renewable energy. The company's investment process include screening process which inludes verification of prerequisites such as financial terms, amount of irradiation, power purchase agreement and feed-in tar …
  • Graham Packaging Company, L.P.:企業の戦略・SWOT・財務情報
    Graham Packaging Company, L.P. - Strategy, SWOT and Corporate Finance Report Summary Graham Packaging Company, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • WellCare Health Plans Inc (WCG):製薬・医療:M&Aディール及び事業提携情報
    Summary WellCare Health Plans Inc (WellCare) is a managed care services provider which focuses on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs. The company offers Medicaid health plans, Medicare Advantage (MA) coordina …
  • Vital Images Inc:企業の戦略的SWOT分析
    Vital Images Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Dunelm Group plc (DNLM):企業の財務・戦略的SWOT分析
    Dunelm Group plc (DNLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Luna Innovations Inc (LUNA):企業の製品パイプライン分析
    Summary Luna Innovations Inc (Luna) is an optical technology development company that research, develops and commercializes speed optics and fiber optic test products. The company provides products such as fiber optic sensing products, fiber optic test and measurement products, high speed optical pr …
  • JD Sports Fashion Plc:企業のM&A・事業提携・投資動向
    JD Sports Fashion Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JD Sports Fashion Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • 88 Energy Ltd (88E):石油・ガス:M&Aディール及び事業提携情報
    Summary 88 Energy Ltd (88 Energy), formerly Tangiers Petroleum Ltd, is an exploration and production company that develops oil-rich provinces. The company offers discovery, exploration and development of onshore oil projects. It has oil and gas assets in Morocco and Australia. 88 Energy’s Morocco pr …
  • UGI Corp (UGI):企業の財務・戦略的SWOT分析
    UGI Corp (UGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Pulmagen Therapeutics LLP:製薬・医療:M&Aディール及び事業提携情報
    Summary Pulmagen Therapeutics LLP (Pulmagen) formerly Argenta Discovery Ltd, is a development stage pharmaceutical company, which develops oral and inhaled medicines for chronic respiratory diseases. The company’s product pipeline includes oral CRTh2 antagonists, inhaled bronchodilators, inhaled per …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆